ALT
Altimmune, Inc.
Biotechnology
Market Cap$343M
5Y Perf.-75.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ALT vs GPCR
Revenue, margins, valuation, and 5-year total return — side by side.
GPCR
Structure Therapeutics Inc.
Biotechnology
Market Cap$2.25B
5Y Perf.+53.0%
ALT vs GPCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ALT | GPCR |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $343M | $2.25B |
| Revenue (TTM) | $41K | $0.00 |
| Net Income (TTM) | $-88M | $-170M |
| Gross Margin | -364.5% | — |
| Operating Margin | -2304.6% | — |
| Total Debt | $34M | $6M |
| Cash & Equiv. | $44M | $800M |
ALT vs GPCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ALT
GPCR
| Stock | Feb 23 | May 26 | Return |
|---|---|---|---|
| Altimmune, Inc. (ALT) | 100 | 24.5 | -75.5% |
| Structure Therapeut… (GPCR) | 100 | 153.0 | +53.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALT vs GPCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GPCR leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Altimmune, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
ALT
Altimmune, Inc.
The Growth Play
ALT is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 105.0%, EPS growth 25.4%
- 12.1% 10Y total return vs GPCR's 50.4%
- 105.0% revenue growth vs GPCR's -18.6%
Best for: growth exposure and long-term compounding
GPCR
Structure Therapeutics Inc.
The Income Pick
GPCR carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.89
- Lower volatility, beta 0.89, Low D/E 0.4%, current ratio 24.81x
- Beta 0.89, current ratio 24.81x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ALT | 105.0% revenue growth vs GPCR's -18.6% |
| Quality / Margins | GPCR | 2.3% margin vs ALT's -2.1K% |
| Stability / Safety | GPCR | Beta 0.89 vs ALT's 1.39, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | GPCR | +45.8% vs ALT's -46.7% |
| Efficiency (ROA) | GPCR | -14.4% ROA vs ALT's -41.7%, ROIC -30.3% vs -46.7% |
ALT vs GPCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2021
Segment breakdown not available.
ALT vs GPCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGPCRLAGGINGALT
ALTAltimmune, Inc.
1leads
GPCRStructure Therapeutic…
3leads
6 Total Categories
CATEGORYLEADERvs ALTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GPCR7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
GPCR4/6
Risk & VolatilityBeta, volatility, and downside exposure
GPCR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ALT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ALT and GPCR operate at a comparable scale, with $41,000 and $0 in trailing revenue.
| Metric | ALTAltimmune, Inc. | GPCRStructure Therape… |
|---|---|---|
| RevenueTrailing 12 months | $41,000 | $0 |
| EBITDAEarnings before interest/tax | -$94M | -$209M |
| Net IncomeAfter-tax profit | -$88M | -$170M |
| Free Cash FlowCash after capex | -$68M | -$159M |
| Gross MarginGross profit ÷ Revenue | -364.5% | — |
| Operating MarginEBIT ÷ Revenue | -2304.6% | — |
| Net MarginNet income ÷ Revenue | -2148.6% | — |
| FCF MarginFCF ÷ Revenue | -1654.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +18.2% | -29.6% |
ALT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ALT and GPCR each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ALTAltimmune, Inc. | GPCRStructure Therape… |
|---|---|---|
| Market CapShares × price | $343M | $2.3B |
| Enterprise ValueMkt cap + debt − cash | $333M | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -3.09x | -16.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 8356.77x | — |
| Price / BookPrice ÷ Book value/share | 1.21x | 1.53x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ALT and GPCR each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
GPCR leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
GPCR delivers a -15.1% return on equity — every $100 of shareholder capital generates $-15 in annual profit, vs $-49 for ALT. GPCR carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALT's 0.15x. On the Piotroski fundamental quality scale (0–9), ALT scores 4/9 vs GPCR's 3/9, reflecting mixed financial health.
| Metric | ALTAltimmune, Inc. | GPCRStructure Therape… |
|---|---|---|
| ROE (TTM)Return on equity | -49.4% | -15.1% |
| ROA (TTM)Return on assets | -41.7% | -14.4% |
| ROICReturn on invested capital | -46.7% | -30.3% |
| ROCEReturn on capital employed | -48.0% | -24.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.15x | 0.00x |
| Net DebtTotal debt minus cash | -$9M | -$793M |
| Cash & Equiv.Liquid assets | $44M | $800M |
| Total DebtShort + long-term debt | $34M | $6M |
| Interest CoverageEBIT ÷ Interest expense | -54.74x | — |
GPCR leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
GPCR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GPCR five years ago would be worth $15,038 today (with dividends reinvested), compared to $2,362 for ALT. Over the past 12 months, GPCR leads with a +45.8% total return vs ALT's -46.7%. The 3-year compound annual growth rate (CAGR) favors GPCR at 17.7% vs ALT's -14.4% — a key indicator of consistent wealth creation.
| Metric | ALTAltimmune, Inc. | GPCRStructure Therape… |
|---|---|---|
| YTD ReturnYear-to-date | -12.0% | -42.6% |
| 1-Year ReturnPast 12 months | -46.7% | +45.8% |
| 3-Year ReturnCumulative with dividends | -37.2% | +62.9% |
| 5-Year ReturnCumulative with dividends | -76.4% | +50.4% |
| 10-Year ReturnCumulative with dividends | +1213.1% | +50.4% |
| CAGR (3Y)Annualised 3-year return | -14.4% | +17.7% |
GPCR leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
GPCR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
GPCR is the less volatile stock with a 0.89 beta — it tends to amplify market swings less than ALT's 1.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ALTAltimmune, Inc. | GPCRStructure Therape… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.39x | 0.89x |
| 52-Week HighHighest price in past year | $7.73 | $94.90 |
| 52-Week LowLowest price in past year | $2.56 | $15.80 |
| % of 52W HighCurrent price vs 52-week peak | +40.0% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 46.4 | 27.5 |
| Avg Volume (50D)Average daily shares traded | 4.1M | 951K |
GPCR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ALT as "Buy" and GPCR as "Buy". Consensus price targets imply 264.1% upside for ALT (target: $11) vs 193.5% for GPCR (target: $115).
| Metric | ALTAltimmune, Inc. | GPCRStructure Therape… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $11.25 | $114.75 |
| # AnalystsCovering analysts | 15 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
GPCR leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). ALT leads in 1 (Income & Cash Flow). 1 tied.
Best OverallStructure Therapeutics Inc. (GPCR)Leads 3 of 6 categories
Loading custom metrics...
ALT vs GPCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ALT or GPCR a better buy right now?
Analysts rate Altimmune, Inc.
(ALT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ALT or GPCR?
Over the past 5 years, Structure Therapeutics Inc.
(GPCR) delivered a total return of +50. 4%, compared to -76. 4% for Altimmune, Inc. (ALT). Over 10 years, the gap is even starker: ALT returned +1213% versus GPCR's +50. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ALT or GPCR?
By beta (market sensitivity over 5 years), Structure Therapeutics Inc.
(GPCR) is the lower-risk stock at 0. 89β versus Altimmune, Inc. 's 1. 39β — meaning ALT is approximately 56% more volatile than GPCR relative to the S&P 500. On balance sheet safety, Structure Therapeutics Inc. (GPCR) carries a lower debt/equity ratio of 0% versus 15% for Altimmune, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ALT or GPCR?
On earnings-per-share growth, the picture is similar: Altimmune, Inc.
grew EPS 25. 4% year-over-year, compared to -2. 6% for Structure Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ALT or GPCR?
Structure Therapeutics Inc.
(GPCR) is the more profitable company, earning 0. 0% net margin versus -2148. 6% for Altimmune, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GPCR leads at 0. 0% versus -2304. 6% for ALT. At the gross margin level — before operating expenses — GPCR leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ALT or GPCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ALT or GPCR better for a retirement portfolio?
For long-horizon retirement investors, Altimmune, Inc.
(ALT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1213% 10Y return). Both have compounded well over 10 years (ALT: +1213%, GPCR: +50. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ALT and GPCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ALT is a small-cap high-growth stock; GPCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.